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Abstract 
There are now over a dozen disease modifying therapies (DMTs) available to treat multiple sclerosis 
(MS). They vary in efficacy and safety as well as in cost.  
The literature on the cost effectiveness of these is often confusing and contradictory. There is a lack 
of quality evidence enabling the comparison of different DMTs. There are scarce randomised 
controlled trials which look at one DMT compared with another that is not IFN or GA. There is also a 
lack of systematic reviews comparing the efficacy and safety of different DMTs. This makes it difficult 
to perform good quality cost-effectiveness analyses (CEAs). Furthermore, CEAs in and of themselves 
are difficult to interpret or compare due to the variation in methods and cost estimations as well as 
the use of outcome measures which cannot be proven over a reasonable timeframe. 
This review looks at the different DMTs available for MS and attempts to draw some conclusions on 
their cost-effectiveness. It also considers the costs and benefits of front loading the cost of treatment 
for MS by using more expensive and effective treatment earlier on. 
  
Pre-submission 
Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic autoimmune inflammatory condition of the central nervous system 
(CNS). It is a pathophysiological process of inflammation, demyelination and neurodegeneration (1). 
It can cause severe disability as function of the CNS deteriorates (1). Until the 1990s, treatment for 
MS consisted only of symptomatic control, usually a short course of high dose steroids during 
exacerbations of the disease (2). MS attacks would lead to progressively worsening disability and early 
death (3). Since then, a multitude of disease modifying therapies (DMTs) have been developed that 
can slow the course of the disease. These drugs (Table 1) are high-cost and not without their own risks, 
but are now widely used to treat relapsing-remitting forms of MS (RRMS). 
Diagnosis and Clinical Course 
MS is diagnosed when clinical features and investigations indicate there is focal demyelination 
occurring in more than one location and on more than one occasion, such that there is dissemination 
in space and dissemination in time (4). Diagnosis of MS often requires the exclusion of other possible 
diagnoses as presentation is varied (5). Clinical features of MS are many and include motor, sensory 
and autonomic disturbances (1). Most commonly, MS presents with an acute attack of demyelination 
resulting in neurological dysfunction (1). In 80% of cases, this will resolve before subsequent attacks 
occur (1). This is the relapsing-remitting course of the disease. Over time, recovery between episodes 
diminishes and symptoms become progressively worse without recovery and this is termed secondary 
progressive MS (SPMS). About 15-20% of people with MS will have a progressive course from onset, 
known as primary progressive MS (PPMS) (1).  
Pathogenesis 
There are several proposed mechanisms by which CNS autoimmunity may be initiated in MS. 
Molecular mimicry may initiate the process by which autoreactive T cells are stimulated by 
autoantigens (6). By another proposed mechanism, antigens, such as glial or neural proteins may drain 
into cervical lymph nodes via the glymphatic drainage system (7, 8). Once in the cervical lymph nodes, 
these antigens are presented to autoreactive T cells by antigen presenting cells (APCs) (6). There 
seems to be a failure of regulatory T cells to suppress autoreactive T cells upon activation by an 
autoantigen (9). These autoreactive T cells are able to extravasate into the CNS and they are then re-
activated locally, causing the release of cytokines which promote recruitment of microglia and directly 
cause damage to myelin and axons (10). Autoreactive T cells will also activate B cells and a humoral 
response will further add to inflammatory cell recruitment and contribute to damage to myelin and 
axons (11). Alternatively, it may be that memory B cells are the major driving force behind the 
inflammatory phase in MS and present antigens to T cells or directly damage the CNS via toxic 
molecules or stimulate the innate immune response (12, 13). Nearly all DMTs seem to deplete 
memory B cells, and the degree of depletion can be correlated to the efficacy of the drug (12, 13). 
Impact 
MS carries a huge burden for those afflicted with the disease and those close to them. People with 
MS experience a decreased quality of life, and life in the most severe stages of MS can be considered 
to be worse than death (14, 15). Not only do people with MS suffer from physical disability, cognitive 
impairment can also occur from the earliest stages of the disease onwards (16). People with MS are 
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more likely to suffer from anxiety and depression than the general population, and they are also more 
likely to commit suicide (17, 18). Furthermore, people with MS are 40% more likely to get a divorce 
compared to matched controls that did not have MS (19). 
MS has an effect on the ability of people to work full-time and in most cases eventually leads to 
unemployment. A cost-of-illness study carried out in 2017 looking at data from 16,808 people with 
MS across 16 European countries found that overall average unemployment was 68% (20).  
Relapses can be disabling for people with MS and costly for healthcare systems. In the 2017 European 
study, 13% of people had experienced a relapse and 7.5% had been admitted to hospital as an 
inpatient in the last 3 months (20). Overall, 57% of people were using DMTs, with usage varying by 
country from 26-79% (20).  
The 2017 study found that in the UK the total annual cost to society ranged from £11,400 (€12,800) 
for mild disease (EDSS 0-3) to £22,700 (€25,400) for the moderate disease group (EDSS 4-6.5) and 
£36,500 (€40,900) for the severe disease group (EDSS 7-9) (21). Overall, the average cost by disease 
severity across Europe was €22,800, €37,100 and €57,500 for mild, moderate and severe disease (20). 
For less severe disease, the majority of direct costs were due to health care usage, whereas informal 
care costs accounted for most of the direct costs in more severe disease (20). Production losses 
accounted for 39%, 45% and 33% of total costs for mild, moderate and severe disease groups 
respectively (20). 
 
Table 1: Characteristics of Disease Modifying Therapies for Multiple Sclerosis 
DMT Dose Pivotal trial efficacy MoA Side effects Monitoring Annual 
Cost 
(UK)* 
First year 
Cost (US)  
(Year 1 
WAC) 
EMA 
Licensing 
IFNb-1a 
 
(Rebif s.c. 
injection) 
 
(Avonex i.m. 
injection) 
Weekly 
i.m. 
injection 
(30µg)  or 
 
thrice 
weekly 
s.c. 
injection 
(20 or 
44µg) 
s.c.: PRISMS – 27% 
and 33% reduction 
in ARR compared 
to placebo for the 
22µg and 44µg 
dose groups 
respectively, 
Increased time to 
SAD compared to 
placebo (22) 
 
i.m.: 18% reduction 
in ARR compared 
to placebo, 37% 
reduction in SAD vs 
placebo (23) 
The are several 
proposed mechanisms 
of action for beta-
interferons, including 
inhibition of immune 
cell proliferation, 
inhibition of B and T 
cell activation (24, 25), 
increasing anti-
inflammatory cytokines 
(26) , increasing 
apoptosis of 
autoreactive T cells 
(27) and limiting T cell-
endothelial adhesion 
(28, 29).  
Injection site reactions, 
hepatic impairment, 
depression, flu-like 
symptoms. 
Rarer side effects 
include anaemia, 
thrombocytopenia, 
lymphopenia and 
thrombotic 
microangiopathy (30, 
31).  
There is an association 
with capillary leak 
syndrome in 
undiagnosed 
monoclonal 
gammopathy, which is 
why the Association of 
British Neurologists 
recommend that 
protein electrophoresis 
should be carried out 
prior to commencing 
therapy (32, 33) 
 
FBC, LFT, renal 
function, blood 
pressure at 
baseline and 
every 3-6 months 
Protein 
electrophoresis at 
baseline (33, 34) 
Rebif: 
20/44µg 
£9,088 
/£12,068 
 
Avonex: 
£9,061 
 
Rebif: 
$86,416 
 
Avonex: 
$81,965 
RRMS 
IFNb-1b 
(Betaseron or 
Extavia) 
s.c. 
injection 
every 
34% reduction in 
ARR compared to 
placebo, no 
   Betaseron 
And 
Extavia: 
£7,264 
Betaseron: 
$86,659 
Extavia: 
$72,359 
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other day 
(250µg) 
significant effect on 
SAD (35) 
  
Pegylated 
IFNb-1a 
(Plegidry) 
s.c. 
injection 
every two 
weeks 
(125µg) 
ADVANCE – 35% 
reduction in ARR 
and a 39% 
reduction in 3-
month SAD 
compared to 
placebo (36) 
 Flu like symptoms, 
headache, injection site 
reactions, raised liver 
enzymes and 
depression are common 
side effects 
Rarer side effects 
include hypersensitivity 
reactions, seizures, 
injection site reactions, 
renal damage (37) 
Regular 
monitoring of 
FBC, LFT, TFT, 
blood pressure 
and renal 
function (37) 
£8,500 $81,956 RRMS 
Glatiramer 
Acetate (GA) 
(Copaxone or 
Glatopa 
(generic)) 
Daily s.c. 
injection 
(20mg) 
Or thrice 
weekly 
s.c. 
injection 
(40mg) 
29% reduction in 
ARR vs placebo, no 
significant 
difference in SAD 
(38) 
GA promotes apoptosis 
of autoreactive cells by 
increasing levels of a 
strongly suppressive 
subset of regulatory T 
cells (PD1- Treg cells) 
(27). Furthermore GA is 
thought to interfere 
with antigen 
presentation and T cell 
activation, as well as 
increasing anti-
inflammatory cytokines 
(39, 40). 
 
Injection site reactions, 
Symptoms mimicking 
cardiac ischaemia – 
chest tightness, 
shortness of breath, 
palpitations, anxiety 
(31) 
No additional 
monitoring 
required 
£6,700 20mg: 
$86,554 
40mg: 
$76,024 
 
20mg 
Glatopa 
(generic): 
$63,193 
RRMS 
Fingolimod 
(Gilenya) 
Daily oral 
tablet 
(0.5mg) 
 
FREEDOMS II – 48% 
reduction in ARR 
compared to 
placebo, no 
significant 
reduction in SAD 
(41) 
 
TRANSFORMS – 
52% reduction in 
ARR compared to 
i.m. IFNb1a, no 
significant 
difference in SAD 
(42) 
 
Fingolimod is a 
sphingoside-1-
phosphate (S1P) 
receptor antagonist. 
S1P receptors are 
expressed in a variety 
of cells including 
lymphocytes, neurons 
and astroglia. Binding 
of S1P to S1P receptors 
mediates lymphocyte 
migration out of lymph 
glands, and this process 
is disrupted by 
fingolimod as it is an 
S1P analogue. This 
mainly affects central 
memory T cells and 
naïve T cells as these 
are more likely to re-
circulate through 
lymph glands (43).  
First dose bradycardia, 
First and second degree 
atrioventricular block, 
Macular oedema, 
Lymphopenia, 
Infections,  
Elevated liver enzymes, 
Hypertension (34, 41) 
Rarely PML (44) 
MRI, ECG, VZV 
IgG serology, 
pregnancy test, 
ophthalmology 
testing, FBC, LFT 
and blood 
pressure at 
baseline 
Regular 3-
monhtly FBC, LFT 
and 
ophthalmology 
during therapy 
(34, 44, 45) 
£19,169 
 
$82,043 
 
2nd line in 
HARRMS, 
or 1st line 
in RESMS 
 
Teriflunomide 
(Aubagio) 
Daily oral 
tablet 
(14mg) 
TOWER – 36.3%  
reduction in ARR 
compared to 
placebo, reduced 
risk of SAD by 
31.5% (46) 
 
TEMSO –  
Reduced ARR by 
31.5% compared to 
placebo, 
Reduced risk of 
SAD by 29.8% (47) 
 
TENERE –  
No difference in 
ARR compared to 
s.c. IFNb1a (48) 
Teriflunomide is 
thought to inhibit 
proliferation of 
activated T cells by 
inhibiting pyrimidine 
synthesis by the 
enzyme DHODH 
(dihydroororate 
dehydrogenase) (49).  
Elevated liver enzymes, 
Hair thinning, 
Nausea, 
Diarrhoea, 
Hypertension, 
Peripheral neuropathy 
(34, 46) 
 
Baseline FBC, LFT, 
pregnancy test, 
TB, blood 
pressure 
First 6 months of 
therapy: monthly 
FBC, LFT 
After 6 months: 
FBC and LFT 
every 6 months 
(34) 
£13,529. $76,612 RRMS 
Dimethyl 
fumarate 
(Tecfidera) 
120 mg 
twice daily 
oral 
DEFINE –  Dimethyl fumarate has 
anti-inflammatory 
effects, by affecting 
Nausea, 
Diarrhoea, 
Flushing (59), 
Baseline FBC 
and LFT (34) 
£17,898 $82,977 RRMS 
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tablet; 
increased 
to 240 mg 
twice daily 
after 7 
days 
53% reduction in 
ARR compared to 
placebo, 
38% reduction in 
risk of SAD (50) 
 
CONFIRM –  
44% reduction in 
ARR compared to 
placebo, 
Significant 
reduction in ARR 
compared to GA, 
No reduction in 
SAD (51) 
cytokine release and 
immune cell 
differentiation (52-56). 
It may also have 
neuroprotective 
antioxidant effects via 
Nrf2 (nuclear 
(erythroid-derived 2) 
related factor) 
pathways. In vitro 
studies showed that 
dimethyl fumarate 
protected neurones 
and glial cells against 
oxidative stress (57), 
and that this effect was 
lost in Nrf2 deficient 
cells (58). In vivo 
studies in EAE mice 
showed raised levels of 
Nrf2 and improved 
neuronal survival which 
was not seen in Nrf2 
deficient mice (57). 
Rarely PML (60) Baseline MRI 
(60) 
Monitoring of 
white cell count is 
necessary as 
cases of PML 
have been 
reported in 
association with 
lymphopenia (61, 
62) 
Natalizumab 
(Tysabri) 
300mg i.v. 
infusion 
every 4 
weeks. 
AFFIRM – 68% 
reduction in ARR 
compared to 
placebo, and a 42% 
reduction in risk of 
SAD (63) 
Natalizumab is a 
monoclonal antibody 
directed against α4β1 
integrin, an adhesion 
molecule involved in 
the extravasation of 
leukocytes across the 
BBB.  
Mild infusion associated 
symptoms – headache 
and fever, 
Hypersensitivity 
reaction requiring 
discontinuation of 
infusion (34), 
Cases of hepatic injury 
have been reported 
(37) 
The risk of PML after 
two years of therapy is 
1 in 100 in JCV 
seropositive patients 
who have received prior 
immunosuppressive 
treatment (64), 
Neutralising antibodies 
causing delayed 
hypersensitivity and 
reduced efficacy (65) 
MRI at baseline, 
then every 3-12 
months during 
therapy based on 
risk followed by 
one 3-6 months 
post-therapy (66) 
JCV serology 
every 6 
months(66) 
Consider anti-
natalizumab 
antibody testing 
after 6 months 
(65) 
£14,730 
annually 
$78,214 2nd line 
for 
HARRMS 
or 1st line 
for 
RESMS 
Alemtuzumab 
(Lemtrada) 
First 
annual 
course is 
60mg via 
i.v. 
infusion 
over 5 
days. 
Second 
annual 
course is 
36mg via 
i.v. 
infusion 
over 3 
days. 
CARE MS I – 
(Alemtuzumab as 
1st line therapy) 
54.9% reduction in 
ARR and a 30% 
reduction in risk of 
SAD compared to 
44µg s.c. IFNb1a 
(67) 
 
CARE MS II – 
(Alemtuzumab as 
2nd line therapy)  
49.4% reduction in 
ARR and a 42% 
reduction in risk of 
SAD compared with 
44µg s.c. IFNb1a 
(68) 
Alemtuzumab is a mAb 
targeting CD52, a 
surface marker on 
lymphocytes and 
monocytes. 
Alemtuzumab 
treatment depletes 
lymphocytes and 
monocytes which 
subsequently replete 
over a period of time, 
at different rates – 
CD4+ T cells take more 
than 5 years to reach 
pre-treatment levels 
(69). B cells replete 
over three months and 
then rise beyond pre-
treatment levels, and 
this is thought to 
contribute to the 
secondary autoimmune 
complications which 
frequently follow 
alemtuzumab therapy 
(69, 70). 
Infusion related 
reactions (90%) - may 
warrant pre-treatment 
with steroid, 
antihistamine and 
paracetamol (71), 
Infections, 
Secondary autoimmune 
conditions develop in 
up to 50% of patients 
after 2 years of therapy 
(70), 
Neutralizing antibodies 
occur in up to 80% of 
cases after second 
annual course (68) 
Monthly blood 
tests including 
FBC, TFT, LFT 
Consider testing 
for neutralizing 
antibodies (71)  
£56,360 
for full 
two year 
course 
$103,749 Active 
RRMS 
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Ocrelizumab 
(Ocrevus) 
600mg i.v. 
infusion 
every 6 
months 
OPERA I and II– 
46% -47% 
reduction in ARR 
and 40% reduction 
in risk of SAD 
compared to IFNb 
(72) 
 
ORATORIO –  
24% and 25% 
reduction in risk of 
SAD at 12 and 24 
weeks respectively 
compared to 
placebo (73) 
Ocrelizumab targets 
CD20, a B cell 
progenitor antigen, and 
thereby depletes B cells 
(12) 
Infusion-related 
reactions, 
Infections (72) 
FBC (74) £19,160 
(£4790 
per 
300mg) 
$65,000 RRMS 
PPMS 
Cladribine  
(Mavenclad)  
1 or 2 
10mg oral 
tablet 
once per 
day for 
four or 
five days 
of 2 
treatment 
weeks 
each year 
for a total 
dose of 
3.5mg/kg 
over 2 
years 
CLARITY – 57.6% 
and 54.5% 
reduction in ARR 
compared to 
placebo for the 
3.5mg/kg and the 
5.25mg/kg groups 
respectively. 33% 
and 31% reduction 
in risk of SAD for 
the 3.5mg/kg and 
5.25mg/kg groups 
respectively 
compared to 
placebo (75) 
Cladribine is an 
analogue of 
deoxyadenosine, which 
is metabolised to an 
active compound which 
causes cell death by 
incorporating into DNA 
and inhibiting DNA 
repair. It rapidly 
depletes T and B cells 
(76) 
lymphopenia, infections 
– notably herpes zoster 
infections (77) 
FBC 
Screen for HIV, TB 
and Hepatitis 
before 
commencing 
treatment (78) 
 
£2,047.24 
per 10mg 
tablet: 
Total cost 
of 
£50,157 
for the 2 
year 
course for 
a 70kg 
person 
N/A HARRMS 
WAC = wholesale acquisition cost; s.c. = subcutaneous; i.m. = intramuscular; i.v. = intravenous; FBC = full blood count; LFT = liver function tests; TFT = thyroid function 
tests; PML = progressive multifocal leukoencephalopathy; JCV = John Cunningham virus; VZV = varicella zoster virus; TB = tuberculosis; RRMS = relapsing-remitting 
multiple sclerosis; HARRMS = highly active relapsing remitting multiple sclerosis; RESMS = rapidly evolving severe multiple sclerosis; ARR = Annualised Relapse Rate, 
Relapses are usually defined as worsening of neurological signs and symptoms lasting at least 24 or 48 hours, not associated with fever or infection, on a background 
of at least 30 days clinical stability; EDSS = (Kurtzke) Expanded Disability Status Scale; SAD = Sustained Accumulation of Disability, usually defined as 1 or more point 
increase in EDSS sustained for at least 3 or 6 months, or 0.5 point increase if baseline EDSS is over 5.5. 
*= These are list prices, actual prices may be lower 
 
First-line Injectable Therapies 
These were the first DMTs developed for MS, and are still the most commonly used. They are favoured 
as they have a good safety profile (see Table 1) and have been in clinical use the longest. However, 
they are less effective than most newer DMTs (Table 1) (22, 23, 35, 38). Of course, there are issues in 
simply comparing outcome figures across different trials – with varying methods, patient 
characteristics, outcome definitions, trial lengths performed, safety profiles and trials performed at 
different times over recent history. A recent meta-analysis showed that although IFN and GA were 
generally among the least effective DMTs when looking at Annualised Relapse Rate (ARR) and 3-month 
Sustained Accumulation of Disability (SAD), IFNb1b came out as the most effective in reducing the risk 
of 6-month SAD, and pegylated IFNb1a was third on the list for reducing 6-month SAD (79). Still, cost-
effectiveness models consistently show fewer QALYs gained with IFN and GA compared to other 
DMTs, even though these models generally take into account both ARR and SAD (80-82).  
These drugs were initially deemed by the National Institute for Clinical Excellence (NICE), within the 
UK,  to not meet their cost-benefit threshold, but were provided by the NHS under the risk-sharing 
scheme (RSS), in which the drug would be approved by NICE for use in the NHS if it was found to be 
cost-effective in a 20-year model based off of 10 years of follow-up data, and if not the price of the 
drugs for these patients would be discounted by the manufacturer (83). The outcome of the re-
evaluation by NICE in early 2018 further concluded glatarimer acetate and all the beta interferons 
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except Betaferon are recommended for use in people with RRMS but only if provided with a discount 
under commercial agreement with suppliers (84). Betaferon was not considered to be cost-effective 
(84). 
Oral Therapies 
Current oral therapies for MS include teriflunomide, fingolimod, dimethyl fumarate and oral cladribine 
prodrug (Table 1). Although these oral therapies have the advantage of not being injected, they do 
still require regular blood test monitoring. In terms of effectiveness, Teriflunomide is as effective as 
IFN and GA, whilst dimethyl fumarate and fingolimod are more effective (79). However, these are still 
not as effective as the second-line injectable therapies natalizumab and alemtuzumab (79). The annual 
cost of these drugs varies from £13,500-£25,000, making them relatively expensive compared to IFN 
and GA. Oral cladribine is arguably the most effective of the oral agents for MS (77). In a recent cost 
effective analysis (CEA), cladribine was found to be more cost-effective than alemtuzumab and 
natalizumab (85). This may in part account for the relatively rapid approval of oral cladribine by NICE 
and availability to the NHS shortly following approval by the European Medicines agency. In terms of 
safety, these oral DMTs are all relatively safe compared to DMTs such as natalizumab and 
alemtuzumab (see Table 1). 
Second-line Therapies 
Natalizumab was the first monoclonal antibody licensed for use in MS. It is one of the most effective 
therapies available (79). At £14,730 annually, it is one of the less expensive DMTs for MS. However, 
this is not taking into account the cost for any additional monitoring required. Indeed, for one CEA the 
price per QALY gained went from 38,000 EUR (£32,000) when looking only at direct healthcare costs, 
to 59,000 EUR (£50,000) when taking into account the extra monitoring required due to the risk of 
progressive multifocal leukoencephalopathy (PML) (80). 
PML is a progressive inflammatory condition in the brain caused by the John Cunningham virus (JCV). 
It can be associated with immunosuppression and a low white cell count (86). Currently, the only 
treatment is to terminate immunosuppressive therapy in order to minimise disease progression. It has 
a high mortality rate, approximately 20-25% at 6 months (87, 88). This is a rare occurrence with 
fingolimod and dimethyl fumarate therapy (44, 89). Though no cases have yet been reported with 
ocrelizumab therapy (unless following natalizumab therapy (90)), PML has been known to occur with 
anti-CD20 antibodies (91). The greatest risk of PML reported so far occurs with natalizumab therapy. 
The risk of PML after two years of therapy is about 1 in 100 in JCV seropositive patients who have 
received prior immunosuppressive treatment (64). Therefore natalizumab therapy requires MRI 
monitoring and JC virus serology status is monitored at 6-monthly intervals whilst on therapy (92). 
Alemtuzumab is another monoclonal antibody that is currently licensed for RRMS. According to a 
recent meta-analysis, it is the most effective treatment for RRMS when looking at outcomes such as 
ARR improvement and preventing disability progression (79). However, due to the fact that disease 
progression is not always defined by the same criteria in different studies, and people in the pivotal 
alemtuzumab trials had a shorter disease course and therefore perhaps more neurological reserve to 
respond to therapy, the evidence for efficacy in preventing disease progression is less reliable (79). 
Significant monitoring is needed as the risk for secondary autoimmunity is as high as 50% of those 
treated with two annual courses (70). The cost of these potential complications is high as they include 
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thyroid autoimmunity, ITP (immune thrombocytopaenic purpura) and renal anti-glomerular basement 
membrane disease (70). These are costly to manage and can lead to severe disability and death (70). 
Furthermore, neutralizing antibodies occur in up to 30% of patients following the first course (68). This 
incidence increases to 80% after the second annual course (68). In many cases neutralizing antibody 
levels decrease over the year between treatment courses, rendering them non-problematic, but in 
some cases they persist causing treatments to be ineffective (68). Repeated courses past two years 
may not be necessary though as effects can last up to 6 years and possibly beyond (93-96). 
Two phase III trials were conducted with ocrelizumab for RRMS, and one for PPMS (72, 73). Its efficacy 
data in these pivotal trials was comparable to current most effective DMTs. SAEs occurred at a similar 
rate as with IFN treatment or placebo, making it relatively safe compared to most other DMTs (72, 
73). However, development of ocrelizumab was halted for rheumatoid arthritis and lupus due to 
deaths from infection (97, 98). It remains to be seen what the long-term safety profile of this drug will 
be like. Currently, it is administered every 6 months, however the phase II extension study suggests 
that like alemtuzumab and oral cladribine, that ocrelizumab may have induction therapy potential 
with long-term benefit from short courses of therapy (12, 13). Although cost-benefit value of 
ocrelizumab is accepted, this agent has yet to be seen as sufficiently cost-effective for treatment of 
PPMS. Although the manufacturers had offered supply to the NHS at a lower price than for use in 
relapsing MS variants, NICE has yet to entertain this model (99).  
Haematopoietic Stem Cell Transplantation 
A recent study showed total suppression of CNS inflammatory processes with autologous 
haematopoietic stem cell transplant (aHSCT), evidenced by a complete lack of relapses in any patients 
during a 7-year follow up period (100). Disability progression was halted in 70% of patients (100). This 
is similar to other studies looking at aHSCT for MS, but the total suppression of CNS immunity had not 
been seen before (101-103). Effects seen have been dramatic, but the procedure is currently reserved 
for last resort cases due to the high associated risk of mortality at around 5% (104), although this can 
be minimised in specialist centres to 1-2% (105). If safety improvements can be made and high efficacy 
results continue to be seen, then the procedure may become more commonplace in the future. 
Cost-Effectiveness Analyses 
The CEAs for MS drugs use models to predict the long-term cost and benefit of drugs based on 
published trial data. There are various issues with this. CEAs can take on the societal or the third-party 
payers perspective. The third party payers perspective includes only the cost of the drug and the cost 
to healthcare providers, whereas societal perspective will include informal care costs and indirect 
costs, such as the cost of unemployment. Thus, changing the perspective will impact the cost-
effectiveness of the drug. A societal perspective is arguably more useful and realistic, but also less 
reliable than the payers perspective. Indeed, methods for estimating costs to society can vary widely 
between CEAs (106). 
Changing the length of time of the model can affect the outcome of CEAs (107), as can using different 
sources for utility values (108). Some models do not account for non-drug care costs or the costs of 
complications and side effects of treatment. Many CEAs fail to transparently describe and justify their 
methods of cost estimation and the limitations of their studies, and sponsored CEAs tend to favour 
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the drug of the sponsor (106, 107). Furthermore, as the payer threshold per QALY is known, health 
economic data may be adapted to fit this threshold. 
A CEA is only as good as the original trial data being used, therefore models using data from longer 
and larger trials with similar study populations are preferable. Head-to-head comparative randomized 
controlled trials (RCTs) are ideal but there is a near total dearth of RCTs comparing any DMT with any 
other DMT other than IFN or GA (79). Yet there are a number of cost-effectiveness models comparing 
various DMTs with each other, using data from separate trials or from historical comparator 
populations (106, 109). However comparisons are emerging following comparisons of real life usage 
using registries such as NARCOMS (North American ) and MSBase (110). 
The RCTs need to minimise the heterogeneity of outcome measures used. Defining SAD by 3 months 
instead of 6 may overestimate the rate of disability progression. Similarly, defining a relapse as lasting 
24 verses 48 h can impact the results. Furthermore, as treatments become more effective these 
outcome measures become less relevant. There has been a move towards inclusion of other end 
points, notably that of the proportion of patients with no evidence of disease activity (NEDA). NEDA 
has been defined as “absence of new or enlarging T2 lesions or T1 gadolinium-enhancing lesions on 
MRI and no sustained EDSS score progression or clinical relapse” (111). In light of the improving 
efficacy of therapies, NEDA has become an important end-point. However, current definitions of NEDA 
may not pick up slight changes in disability progression (112). Furthermore, none of these outcome 
measures take into account the impact of MS and treatments on things like mental health, working 
status and quality of life, all of which may be more pertinent to look at as treatments are becoming 
more effective at suppressing disease activity as measured by relapses, MRI lesions and EDSS 
progression. As such NEDA evolves as new outcome measures form part of the definition such as brain 
atrophy and neurofilament levels (113). 
A problem with long-term CEAs is that they cannot be challenged in a reasonable timeframe. There 
has been a call recently for manufacturers to support claims from CEAs with a protocol for empirical 
evaluation over a reasonable short-term timeframe, so that decision makers can confirm decisions on 
whether treatments shall be made available in their healthcare system (114). Long-term CEAs are 
arguably more useful to estimate the overall cost-benefit of a drug, especially when looking at whether 
more expensive but effective drugs can be a more cost-effective option in the context of a lifetime. 
However, these predictions cannot be challenged or tested, and as such cannot provide any real 
evidence of cost-effectiveness. Using cost per relapse avoided or year of NEDA instead of QALYs gained 
provides outcomes that can be verified in short-term studies. (83). 
For the reasons outlined above, it is difficult to draw any conclusions from CEAs about which DMT is 
most cost effective.  
Front-Loading of Costs 
Recently, evidence is pointing towards the fact that front-loading of treatment costs in MS may be 
more cost-effective than paying for longer-term treatments, which are cheaper. It seems that drugs 
that are better at depleting memory B cells are more effective, and that induction of depletion may 
be all that is needed, without sustained treatment (12, 76). Furthermore, there is evidence to suggest 
that treating earlier in the disease course is more effective (115).  
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Currently, some of the more expensive and effective DMTs are showing promise as induction 
therapies with repeated courses after 1-2 years not being necessary, thus lowering the cost per QALY. 
Some of the best efficacy results have been seen with drugs such as alemtuzumab, ocrelizumab and 
oral cladribine, and there is evidence for all of these that treatment beyond the first couple of years 
may not be necessary (72, 93-96, 116). This means that though these are among the most expensive 
DMTs for MS, the cost over a lifetime may actually be less than some of the cheaper DMTs that require 
longer periods of treatment (85, 107, 117-119). Furthermore, treating aggressively early on in the 
disease to achieve NEDA may reduce hospital visits and admissions, further reducing the cost to 
healthcare systems and society (120). Indeed, one retrospective cohort study looking at the 
relationship between healthcare costs and disease progression in Italy found that higher care spending 
was associated with reduced progression over a 14 year time period (121). Long-term benefit from 
short treatment cycles means that the DMT are only present for short period and therefore may 
reduce problems of drug-drug interactions with the polypharmacopia of agents that will be needed to 
deal with symptomatic issues and neurorepair and protection. However, problems with these DMTs 
include the fact that they are new and long-term safety has not yet been determined. Furthermore, 
long-term efficacy has not been confirmed beyond a few years.  
Conclusion 
MS is a progressively disabling disease that has a significant impact on quality of life. This has 
implications for the individual with MS, for their families and for Society as people with MS are more 
likely to be unemployed and to require informal care from friends and family. This is in addition to the 
formal healthcare cost of managing the disease and the disability caused by it. Clearly there is a great 
need for treatments that can slow the progression of the disease and prevent disability.  
Current first-line therapies are relatively safe and cheap but less effective compared to second-line 
therapies (79). There may be something to be said for using more expensive therapies that are also 
more effective to reduce the long-term risk of disability and to reduce long-term costs.  Currently it is 
difficult to say what the long term outcomes of different therapies may be as there is not enough long-
term follow-up data. Cost-effectiveness models have aimed to compare DMTs with each other over 
long-term time horizons, but their results are often difficult to interpret or compare across analyses. 
Currently, the drugs with the most benefit tend to be those that carry the most risk and highest price 
tag. It may be worth using more aggressive measures earlier on as front-loading the cost means the 
cost of long-term disability progression is reduced. Further head-to-head RCTs, RCT follow-up studies 
and CEAs are needed to answer these questions, and these need to take on board the 
recommendations that have been made for improving their quality. As patents expire notably on 
chemical small molecules that have low costs, the treatment landscape and cost-effectiveness 
requirements may change (122).  
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